세계의 줄기세포 제조 시장 보고서(2025년)
Stem Cell Manufacturing Global Market Report 2025
상품코드 : 1821703
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,482,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,370,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,257,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

줄기세포 제조 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에 CAGR은 11.9%를 나타낼 것으로 예측되고 300억 3,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 자금 및 투자 증가, 치료제 용도 확대, 세포 기반 치료법 등장, 임상 시험 및 승인 증가, 맞춤형 및 환자별 치료법 발전에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 3D 바이오 프린팅에 주력, 유도만능줄기세포(iPSC) 확대, 자동화 및 로봇 통합, 표준화 및 확장성, 생물반응기 기술적 발전 등이 포함됩니다.

향후 5년간 11.9% 성장 예측은 이전 전망 대비 0.2% 소폭 하락한 수치입니다. 이 하락은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 긴장은 이스라엘과 벨기에에서 개발된 자동화 생물반응기 시스템 및 GMP 등급 성장인자의 가격 상승을 유발하여 미국 세포 치료제 생산을 저해할 수 있으며, 이는 제조 병목 현상과 CAR-T 치료 비용 증가로 이어질 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과가 더욱 광범위하게 될 것입니다.

노인 인구 증가가 줄기세포 제조 시장 성장을 촉진할 것으로 예상됩니다. 노인 인구는 면역력 감축과 노화 영향으로 다양한 건강 문제를 겪는 65세 이상 개인을 의미합니다. 이 인구 집단은 만성 질환 위험이 높으며, 줄기세포 제조는 이러한 질환 퇴치에 핵심적인 역할을 할 수 있습니다. 예를 들어, 2024년 1월, 케냐에 본부를 둔 비영리 단체인 인구문제연구소는 65세 이상의 미국인 수가 2022년 5,800만명에서 2050년에 8,200만명으로 47% 증가할 것으로 예측했습니다고 보고했습니다. 또한 이 연령대가 총 인구에서 차지하는 비율은 같은 시기에 17%에서 23%를 나타낼 것으로 예측되고 증가할 것으로 예측됩니다. 따라서 확대되는 고령 인구는 줄기세포 제조 시장의 성장에 상당한 촉진요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Stem cell manufacturing involves the technologies required to transition stem cell tissue culture from laboratory settings to clinical applications, ensuring controlled, reproducible, automated, validated, and safe production for therapeutic purposes.

The primary products within stem cell manufacturing comprise consumables, instruments, and stem cell lines. Consumables are utilized in growing new cells within culture media, contributing to applications in drug development, tissue culture, gene therapy, and toxicity testing. These consumables serve diverse purposes across research, clinical applications, and cell and tissue banking. They are used by a range of end-users including pharmaceutical and biotechnology companies, academic institutes, research laboratories, contract research organizations, hospitals and surgical centers, as well as cell and tissue banks.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The stem cell manufacturing market research report is one of a series of new reports from The Business Research Company that provides stem cell manufacturing market statistics, including stem cell manufacturing industry global market size, regional shares, competitors with a stem cell manufacturing market share, detailed stem cell manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell manufacturing industry. This stem cell manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stem cell manufacturing market size has grown strongly in recent years. It will grow from $17.5 billion in 2024 to $19.17 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to advancements in biotechnology, research and development initiatives, clinical trials and therapeutic applications, regulatory framework establishment, investment in infrastructure.

The stem cell manufacturing market size is expected to see rapid growth in the next few years. It will grow to $30.03 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to increased funding and investments, growing therapeutic applications, emergence of cell-based therapies, rise in clinical trials and approvals, customized and patient-specific therapies. Major trends in the forecast period include focus on 3d bioprinting, expansion in induced pluripotent stem cells (ipscs), automation and robotics integration, standardization and scalability, bioreactor technology advancements.

The forecast of 11.9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cell therapy production by inflating prices of automated bioreactor systems and GMP-grade growth factors developed in Israel and Belgium, resulting in manufacturing bottlenecks and higher CAR-T therapy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing geriatric population is anticipated to drive the growth of the stem cell manufacturing market. The geriatric population refers to individuals aged 65 and older, who often experience various health issues due to reduced immunity and the effects of aging. This demographic faces a higher risk of chronic diseases, and stem cell manufacturing can play a crucial role in combating these ailments. For example, in January 2024, the Population Reference Bureau, a nonprofit organization based in Kenya, reported that the number of Americans aged 65 and above is projected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Additionally, this age group is expected to grow its share of the total population from 17% to 23% during the same timeframe. Therefore, the expanding geriatric population is a significant driver of the stem cell manufacturing market's growth.

The expanding biotechnology industry is projected to drive the growth of the stem cell manufacturing market in the future. Biotechnology is a broad and rapidly evolving field that includes a variety of products and services utilizing living organisms or their components to create new technologies and solutions. Stem cell manufacturing represents a quickly advancing sector with the potential to transform the biotechnology landscape by developing innovative therapies and treatments for various diseases. For instance, in June 2024, the BioIndustry Association (BIA), a UK-based national trade association for the life sciences and biotechnology sector, reported that biotech companies in the UK secured £622 million in venture capital during the second quarter of 2024, marking an impressive 259% increase from the previous quarter and a 48% rise compared to the same period last year. Thus, the growth of the biotechnology industry is fueling the expansion of the stem cell manufacturing market.

Technological advancement is a significant trend within the stem cell manufacturing market. Various stakeholders are concentrating on utilizing advanced technologies to remain competitive in the industry. For example, in August 2022, Bluebird Bio Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had approved ZYNTEGLO. This groundbreaking one-time gene therapy is now authorized for treating beta-thalassemia in patients requiring regular red blood cell transfusions. A key feature of this therapy is its ex-vivo method, where a modified beta-globin gene is integrated into the patient's own hematopoietic stem cells, allowing them to produce normal levels of hemoglobin. This innovative treatment aims to achieve transfusion independence, significantly reducing the treatment burden for individuals with beta-thalassemia. The approval of ZYNTEGLO marks a pivotal milestone in gene therapy, potentially providing a cure and improving the quality of life for those affected.

Major companies within the stem cell manufacturing market are actively pursuing the development of innovative products, with a focus on GM-grade protein to attain a competitive advantage. GM-grade protein is a designation indicating that protein powders and related products meet specific standards for quality and safety. A noteworthy example is ACROBiosystems Inc., a US-based provider of recombinant proteins and critical reagents, which, in November 2023, introduced GM-grade DLL4 protein. This recombinant, soluble form of Delta-such as Ligand 4 (DLL4), a crucial signaling molecule in stem cell development and differentiation, signifies a significant milestone for advancing stem cell-based therapies. The availability of GMP-grade DLL4 ensures a high-quality, consistent, and scalable source of this essential protein, known for promoting the self-renewal and expansion of hematopoietic stem cells (HSCs). Its utilization in stem cell cultures enhances the growth and differentiation of HSCs, contributing to advancements in stem cell research and therapies.

In July 2022, Bio-Techne Corporation, a US-based life sciences company, acquired Namocell Inc. for an undisclosed sum. This strategic acquisition enhances Bio-Techne's capabilities in stem cell research and manufacturing by integrating Namocell's innovative platforms, which are crucial for cell and gene therapy development, cell engineering, and single-cell genomics. Namocell Inc. specializes in high-performance systems for single-cell sorting and dispensing.

Major companies operating in the stem cell manufacturing market include Thermo Fisher Scientific Inc., Merck Millipore, Stemcell Technologies, Fujifilm Holdings Corporation, Takara Bio Group, Lonza Group AG, Sartorius AG, Bio-Rad Laboratories, Becton Dickinson and Company, Bio-Techne Corporation, Miltenyi Biotec, Terumo BCT Inc., Corning Inc., Eppendorf AG, ViaCyte Inc., Merck KGaA, Danaher Corporation, Vericel Corporation, American Cryostem Corporation, Cellgenix GMBH, Aspen Neuroscience Inc., Magenta Therapeutics Inc, Pluristem Therapeutics Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., 3D Biomatrix Inc., Worthington Biochemical Corporation, Bico Group

North America was the largest region in the stem cell manufacturing market in 2024. Europe was the second-largest region in the stem cell manufacturing market. The regions covered in the stem cell manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the stem cell manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stem cell manufacturing market consists of sales of adult stem cells (ASCs), human embryonic stem cells (HESCs), induced pluripotent stem cells (iPSCs), and very small embryonic-such as cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stem Cell Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stem cell manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for stem cell manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stem cell manufacturing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Stem Cell Manufacturing Market Characteristics

3. Stem Cell Manufacturing Market Trends And Strategies

4. Stem Cell Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Stem Cell Manufacturing Growth Analysis And Strategic Analysis Framework

6. Stem Cell Manufacturing Market Segmentation

7. Stem Cell Manufacturing Market Regional And Country Analysis

8. Asia-Pacific Stem Cell Manufacturing Market

9. China Stem Cell Manufacturing Market

10. India Stem Cell Manufacturing Market

11. Japan Stem Cell Manufacturing Market

12. Australia Stem Cell Manufacturing Market

13. Indonesia Stem Cell Manufacturing Market

14. South Korea Stem Cell Manufacturing Market

15. Western Europe Stem Cell Manufacturing Market

16. UK Stem Cell Manufacturing Market

17. Germany Stem Cell Manufacturing Market

18. France Stem Cell Manufacturing Market

19. Italy Stem Cell Manufacturing Market

20. Spain Stem Cell Manufacturing Market

21. Eastern Europe Stem Cell Manufacturing Market

22. Russia Stem Cell Manufacturing Market

23. North America Stem Cell Manufacturing Market

24. USA Stem Cell Manufacturing Market

25. Canada Stem Cell Manufacturing Market

26. South America Stem Cell Manufacturing Market

27. Brazil Stem Cell Manufacturing Market

28. Middle East Stem Cell Manufacturing Market

29. Africa Stem Cell Manufacturing Market

30. Stem Cell Manufacturing Market Competitive Landscape And Company Profiles

31. Stem Cell Manufacturing Market Other Major And Innovative Companies

32. Global Stem Cell Manufacturing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Stem Cell Manufacturing Market

34. Recent Developments In The Stem Cell Manufacturing Market

35. Stem Cell Manufacturing Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기